Kenakin T, Boselli C
GLAXO Research Laboratories, Glaxo Inc., Research Triangle Park, North Carolina.
J Pharmacol Exp Ther. 1989 Sep;250(3):944-52.
The antagonism of muscarinic receptor-mediated contraction of rat trachea by a range of muscarinic antagonists was quantified by Schild and resultant analysis. Dose-response curves to carbachol, muscarine and oxotremorine were shifted to the right by gallamine and pirenzepine in a parallel manner with no change in maximal response ostensibly indicating simple competitive inhibition. However, Schild analysis indicated differences in the blockade and estimated pKb values with each agonist for both gallamine and pirenzepine. This suggested either that the responses to these three agonists were mediated by a heterogeneous receptor population in this tissue or that the blockade produced by gallamine and by pirenzepine was not competitive. Further Schild analysis with the muscarinic antagonists scopolamine, atropine, 4-diphenylacetoxy-N-methyl piperidine methiodide and (11 [(2-[(diethylamino)methyl]-1-piperidinyl]acetyl)-5,11- dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine 6-one) with carbachol, muscarine and oxotremorine indicated simple competitive antagonism of a homogeneous population of muscarinic receptors. Therefore, the competitivity of binding of atropine, gallamine and pirenzepine with the scopolamine binding site was measured with the recently reported technique of resultant analysis. With this method the effect of various concentrations of the test antagonist on the antagonism produced by specified concentrations of the reference antagonist scopolamine was measured and the equilibrium dissociation constant of the test antagonist-receptor complex estimated. These data indicated that atropine and scopolamine bind to a common binding site on the muscarinic receptor, but that scopolamine and both gallamine and pirenzepine bind to mutually exclusive sites. This result is mine and pirenzepine are allosteric modulators of muscarinic receptors which bind at sites other than that utilized by agonists.(ABSTRACT TRUNCATED AT 250 WORDS)
通过Schild法及结果分析对一系列毒蕈碱拮抗剂拮抗大鼠气管毒蕈碱受体介导收缩的作用进行了定量研究。加兰他敏和哌仑西平使对卡巴胆碱、毒蕈碱和氧化震颤素的剂量-反应曲线平行右移,最大反应无变化,表面上表明是简单竞争性抑制。然而,Schild分析显示加兰他敏和哌仑西平对每种激动剂的阻断作用及估计的pKb值存在差异。这表明对这三种激动剂的反应要么由该组织中异质性受体群体介导,要么加兰他敏和哌仑西平产生的阻断作用并非竞争性。用毒蕈碱拮抗剂东莨菪碱、阿托品、4-二苯基乙酰氧基-N-甲基哌啶甲基碘化物和(11-[(2-[(二乙氨基)甲基]-1-哌啶基]乙酰基)-5,11-二氢-6H-吡啶并[2,3-b][1,4]苯二氮䓬-6-酮)对卡巴胆碱、毒蕈碱和氧化震颤素进行进一步的Schild分析,表明存在对同质毒蕈碱受体群体的简单竞争性拮抗作用。因此,采用最近报道的结果分析技术测定了阿托品、加兰他敏和哌仑西平与东莨菪碱结合位点的结合竞争性。用该方法测定了不同浓度的受试拮抗剂对特定浓度的参考拮抗剂东莨菪碱产生的拮抗作用的影响,并估计了受试拮抗剂-受体复合物的平衡解离常数。这些数据表明阿托品和东莨菪碱结合于毒蕈碱受体上的共同结合位点,但东莨菪碱与加兰他敏和哌仑西平均结合于互斥位点。该结果表明加兰他敏和哌仑西平是毒蕈碱受体的变构调节剂,它们结合于激动剂所利用位点以外的位点。(摘要截短于250字)